News

‘Breakthrough’ breast cancer treatment can help women live longer
A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...
New three-drug combination 'could help women with aggressive breast cancer live longer'
A new three-drug combination could help women with a common form of aggressive breast cancer live longer, a study has ...
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in ...
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
(EBC) patients receiving Kisqali in 1-year post-treatment analysis1Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients1Rising br ...
Pharmabiz2d
US FDA grants priority review status to Bayer’s sevabertinib to treat patients with HER2-mutant non-small cell lung cancer
US FDA grants priority review status to Bayer’s sevabertinib to treat patients with HER2-mutant non-small cell lung cancer: Berlin Friday, May 30, 2025, 16:00 Hrs [IST] Bayer an ...
The Joplin Globe1d
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer ...
Pharmabiz6d
EMA committee recommends approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
EMA committee recommends approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer: Basel Monday, May 26, 2025, 12:00 Hrs [IST] Roche an ...